CD Projekt: Strong Q3, But Valuation Leaves No Room For Error
CD Projekt delivered strong Q3 2025 earnings driven by Cyberpunk monetization, but accounting-boosted margins and rising development spend raise questions about earnings quality. With no major releases before 2027, the stock’s premium valuation leaves little margin for error.
American Bitcoin: A High-Flying Mining Story With A Valuation That's Running Out Of Road
American Bitcoin is scaling its mining fleet fast, but its valuation is stretched far beyond its Bitcoin reserves. This breakdown explains the real risk-reward behind ABTC’s growth story.
Ubisoft: Tencent's €1.16 Billion Lifeline Erases Debt, But The Turnaround Still Isn't Proven
Ubisoft Entertainment (OTCPK:UBSFY) (OTCPK:UBSFF) erased its net debt through Tencent’s €1.16B investment, but its turnaround remains unproven as execution risk and portfolio dependence persist.
SharpLink Gaming: An Undervalued Ethereum Proxy With 24% Upside
SharpLink Gaming (NASDAQ:SBET) trades below the value of its Ethereum treasury, creating a rare discount for investors seeking ETH-backed equity exposure. This post breaks down the upside and the key drivers behind SBET’s valuation gap.
Capcom: Record First-Half Profitability, Sector-Low Valuation, And 40% Upside (Rating Upgrade)
Capcom’s (OTCPK:CCOEY) (OTCPK:CCOEF) 2025 first-half earnings delivered record profitability, sector-low valuation metrics, and accelerating catalog sales. My analysis breaks down why the stock offers 40% upside for long-term investors.
Niagen Bioscience: A Breakout Quarter That Now Faces Its Biggest Market Shift In Years
Niagen Bioscience (NASDAQ:NAGE) Q3 2025 earnings delivered explosive growth in revenue, margins, and cash flow—just as NMN re-enters the NAD+ market. Here’s what investors need to know about this new competitive pressure.